TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00652093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opana then darvocet then placebo
Description: Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opana then placebo then darvocet
Description: Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo then opana then darvocet
Description: Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then darvocet then opana
Description: Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darvocet then opana then placebo
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darvocet then placebo then opana
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
Study: NCT01411540

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole grains
Description: Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grains
Description: Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
Study: NCT04046484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-1620 along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study: NCT02796950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: P.o. administration of 250 mg acipimox
Study: NCT04486521

Intervention type: DRUG
Intervention: Interleukin 6 (IL6) Antagonist
Description: anti-IL6 alone

Intervention type: DRUG
Intervention: Interleukin 6 (IL6) Antagonist and corticosteroids
Description: anti-IL6 + corticosteroid combination
Study: NCT03342339

Intervention type: OTHER
Group type: OTHER
Intervention: Iowa Gambling Task
Description: Test of Iowa Gambling Task

Intervention type: OTHER
Group type: OTHER
Intervention: Iowa Gambling Task
Description: Test of Iowa Gambling Task
Study: NCT01266902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: 25 mg once daily
Study: NCT04486521

Intervention type: DRUG
Intervention: corticosteroid alone
Description: dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent
Study: NCT00956644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan/amlodipine
Description: Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
Study: NCT02820714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 Laxative
Description: BLI801 Laxative
Study: NCT00570232

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150 mg per day by mouth for 12 months
Study: NCT05151627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KINESIO TAPING
Description: Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONVENTIONAL PHYSICAL THERAPY
Description: Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions.
Study: NCT03784534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical and behavioral testing : Motor recovery progress
Description: NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical and behavioral testing : Motor skills
Description: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical and behavioral testing : Motor skills
Description: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
Study: NCT03586219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid-specific educational patient pamphlets
Description: See prior description
Study: NCT01316536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: provide headphones with music playing
Description: Participants will be provided with music through headphones

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sounds
Description: recorded ICU sounds will be provided to participants through headphones
Study: NCT00095537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panHer
Description: Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
Study: NCT03407209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consumption of local anesthetic measurement
Description: consumption of local anesthetic measurement in both groups

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: consumption of local anesthetic measurement
Description: consumption of local anesthetic measurement in both groups
Study: NCT03201003

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101 powder provided in capsules & sachets
Description: Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder provided in capsules & sachets
Description: Study product formulated to contain only inactive ingredients for use as defined in the protocol
Study: NCT02209636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial cell collection
Description: Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endothelial cell collection
Description: Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
Study: NCT00985452

Intervention type: OTHER
Group type: OTHER
Intervention: GlowCaps Connect system
Description: The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.

Intervention type: OTHER
Group type: OTHER
Intervention: GlowCaps Connect system
Description: The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.

Intervention type: OTHER
Group type: OTHER
Intervention: Glow cap system - deactivated
Description: The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
Study: NCT02997189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTO-104
Description: 12 mg dexamethasone administered intratympanically
Study: NCT02090582

Intervention type: OTHER
Group type: OTHER
Intervention: Structured Palliative Care
Description: Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
Study: NCT00450866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epothilone B
Description: Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
Study: NCT04704765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal breathing training
Description: The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
Study: NCT03988114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonsteroidal Aromatase Inhibitor (NSAI)
Description: Letrozole administered orally or anastrozole administered orally (physician choice)
Study: NCT01962259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT05151627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONVENTIONAL PHYSICAL THERAPY
Description: Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions.
Study: NCT02728778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxin A
Description: Application of botulinum toxin A into the forehead

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture
Description: Application of acupuncture into the forehead
Study: NCT03639051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Lung Denervation (TLD)
Description: Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Medical Care
Description: Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Optimal Medical Care
Description: Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
Study: NCT01200134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET-scanning
Description: Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
Study: NCT04545203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage
Description: Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
Study: NCT01017575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 10 mg, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 10 mg, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 60 mg, daily, 24-48 weeks
Study: NCT03649581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compare the two groups of schizophrenic patients
Description: Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
Study: NCT04746183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid
Description: Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
Study: NCT01962259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT03649581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compare the two groups of schizophrenic patients
Description: Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compare the two groups of schizophrenic patients
Description: Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
Study: NCT04746183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: ALG-097558 600 mg Twice a day (BD) for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: ALG-097558 600 mg Twice a day (BD) for 5 days
Study: NCT03649581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compare the two groups of schizophrenic patients versus volunteers
Description: compare the results of the schizophrenic patient group with healthy volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compare the two groups of schizophrenic patients versus volunteers
Description: compare the results of the schizophrenic patient group with healthy volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compare the two groups of schizophrenic patients versus volunteers
Description: compare the results of the schizophrenic patient group with healthy volunteers
Study: NCT01017575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 60 mg, daily, 24-48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
Study: NCT02011958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: 40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)
Study: NCT01017575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
Study: NCT03858465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: intravenous 25 mg of ephedrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: intravenous 0,3 mg of phenylephrine
Study: NCT03616171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP-Extend intervention
Description: 1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
Study: NCT00576212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supportive call
Description: Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
Study: NCT03500679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo as an IM injection on Days 1 and 181.
Study: NCT04746183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558 and Remdesivir
Description: ALG-097558 600 mg Twice a day (BD) for 5 days Remdesivir will be administered once daily by intravenous infusion over 30 to 120 minutes. 200 mg will be given on day 1 and 100 mg on day 2 and day 3.